Which statement accurately describes common signs of stimulant intoxication, withdrawal symptoms, and the typical management approach?

Which statement accurately describes common signs of stimulant intoxication, withdrawal symptoms, and the typical management approach?

• A. Intoxication commonly presents with euphoria, tachycardia, hypertension, and agitation.
• B. Withdrawal typically features hypersomnia and lack of craving.
• C. Management of stimulant withdrawal is best accomplished with a specific medication routinely recommended.
• D. There are highly effective pharmacotherapies for stimulant withdrawal.

Answer: (A)

Stimulant intoxication is typically marked by a sense of euphoria or heightened mood, along with autonomic arousal such as tachycardia and hypertension, and often agitation or restlessness. This pattern matches the statement that intoxication commonly presents with euphoria, tachycardia, hypertension, and agitation. For withdrawal, the usual picture includes fatigue, sleep disturbance or hypersomnolence, and increased appetite, with craving for the drug commonly present. So a claim of hypersomnia with a lack of craving isn’t accurate. Regarding management, there isn’t a specific medication routinely recommended to treat stimulant withdrawal. Care is supportive and symptom-driven, focusing on safety, sleep, nutrition, mood symptoms, and psychosocial interventions; benzodiazepines may be used for agitation in the acute phase, but no highly effective, universally endorsed pharmacotherapy exists. This is why options asserting a specific withdrawal medication or highly effective pharmacotherapies aren’t correct.

Stimulant intoxication is typically marked by a sense of euphoria or heightened mood, along with autonomic arousal such as tachycardia and hypertension, and often agitation or restlessness. This pattern matches the statement that intoxication commonly presents with euphoria, tachycardia, hypertension, and agitation.

For withdrawal, the usual picture includes fatigue, sleep disturbance or hypersomnolence, and increased appetite, with craving for the drug commonly present. So a claim of hypersomnia with a lack of craving isn’t accurate.

Regarding management, there isn’t a specific medication routinely recommended to treat stimulant withdrawal. Care is supportive and symptom-driven, focusing on safety, sleep, nutrition, mood symptoms, and psychosocial interventions; benzodiazepines may be used for agitation in the acute phase, but no highly effective, universally endorsed pharmacotherapy exists. This is why options asserting a specific withdrawal medication or highly effective pharmacotherapies aren’t correct.